Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Vasculitic Neuropathy Clinical Presentation

  • Author: Abbas Mehdi, MD; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
 
Updated: Feb 05, 2015
 

History

Vasculitic neuropathy can present as acute/subacute relapsing, progressive, or relapsing progressive neuropathy.

  • Asymmetric or multifocal painful sensorimotor neuropathy is the most common presentation.
  • Duration of neuropathy symptoms before biopsy or diagnosis ranges from 3 weeks to 5 years (mean 8 ± 11 mo).
  • Constitutional symptoms, including weight loss, anorexia, fatigue, arthralgias, myalgias, and fevers, occur in about two thirds of patients.
  • Neuropathies are painful in more than 80% of patients.
  • About 75% of patients experience at least one acute attack, but about 25% have an indolent slowly progressive course from onset. In about half of all patients, the neuropathy follows an acute relapsing course.
  • Typically, the initial symptom of vasculitic neuropathy is acute pain poorly localized in the affected area or limb. Deep aching and burning pain or tingling in the affected nerve distribution appears a few days later. This is followed by weakness in the distribution of the involved nerve.
Next

Physical

A thorough neurologic examination can assist in localizing the involved nerve(s). In general, the patient presents with asymmetric neurological symptoms involving the peripheral nerve(s), with pain and dysesthesias as initial symptoms followed by weakness.

Weakness in vasculitic neuropathy is mostly focal and presents acutely. On examination, about three quarters of patients have an asymmetric polyneuropathy, either as a multiple mononeuropathy or, less commonly, as an asymmetric polyneuropathy (ie, overlapping multiple mononeuropathies).

  • Legs are more commonly involved than arms. Distal involvement is more frequent than proximal involvement.
  • Cranial nerve involvement occurs in 8% of patients, typically involving cranial nerve VII. Asymmetrical lumbosacral plexopathy occurs in 8%. In a small percentage of patients, pure dermatomal sensory loss can also be involved.
  • A proximal symmetric polyneuropathy is the least frequent presentation.
  • Pure motor neuropathy is almost unheard of.
  • Vasculitic neuropathy is unlikely in patients with no asymmetries, pure motor involvement, no pain, and entirely proximal findings.
  • Peroneal nerve: Patient has weakness of foot dorsiflexion and usually presents with foot drop or slapping gait. [21]
  • Tibial nerve: Patient has weakness of foot plantar flexion and inversion. Patient may present with unstable gait.
  • Ulnar nerve: Patient is unable to spread fingers and flex the distal phalanx of the fourth and fifth digits. Weakness of other ulnar-innervated intrinsic hand muscles also is noted.
  • Median nerve: Patient displays weakness of finger and wrist as well as weakness of other median-innervated intrinsic hand muscles.
  • Radial nerve: Wrist drop is the most striking clinical presentation of radial nerve palsy. Elbow extension weakness also may be present.

Sensory findings are frequent and usually are the initial presentation of vasculitic neuropathy. Whereas most patients exhibit mixed sensorimotor findings on examination, about 10% have a pure or predominant sensory neuropathy. Both large-fiber and small-fiber sensory modalities are affected in about 90%, with predominant large-fiber loss in the rest.

  • Burning dysesthetic pain over the distribution of involved nerve is associated with altered or decreased sensation. Large sensory fiber involvement is seen frequently, presenting as decreased vibration sensation and proprioception in affected limbs.
  • Patients with a previous misdiagnosis or those presenting after the acute inflammatory phase has subsided can present with neuropathic pain. This can be mild tingling or numbness to severe dull or burning pain with or without sensory loss.

Hyporeflexia or areflexia, which can be asymmetric, is observed.

Findings inconsistent with a diagnosis of vasculitic neuropathy include the following:

  • Acute onset of symmetric motor weakness
  • Sharp sensory level
  • Bowel and bladder dysfunction
  • Spontaneous remission
Previous
Next

Causes

Causes of vasculitic neuropathy can be classified on the basis of size of the vessels or primary versus secondary vasculitis. A simple classification is based on systemic vasculitis, causing vasculitic neuropathy with other constitutional symptoms or serologic abnormalities, versus nonsystemic vasculitis, which presents as neuropathy only.

Systemic vasculitis

Systemic necrotizing vasculitis

These vasculitides classically involve small and medium-sized arteries affecting multiple organ systems, including the peripheral and central nervous systems. Polyarteritis nodosa is the most common necrotizing vasculitis, with greater than 50% involvement of peripheral nerves. The necrotizing vasculitides include the following:

Hypersensitivity vasculitis

These vasculitides classically involve small vessels, including capillaries, arterioles, and venules. They rarely cause irreversible dysfunction of vital organs and have better prognosis than systemic necrotizing vasculitides. Trigger is usually endogenous or exogenous antigen exposure. Cutaneous manifestations dominate the clinical picture but involvement of other organs and the peripheral nervous system also is noted. The hypersensitivity vasculitides include the following:

Giant cell arteritides

These vasculitides classically involve large and medium-sized vessels. Giant cell formation with mononuclear cell infiltrates is seen frequently. Peripheral neuropathy is rare and is seen in less than 15% of patients with temporal arteritis. The giant cell arteritides include the following:

Connective tissue disease

Patients with connective tissue disease can present with systemic necrotizing vasculitis or hypersensitivity vasculitis. Rheumatoid arteritis (RA) is the connective tissue disease that most often causes vasculitis. Vasculitis develops in 8-25% of patients with RA, usually 10-15 years after onset of RA. Overall, vasculitic neuropathy occurs in 40-50% of patients with systemic vasculitis. Systemic lupus erythematous presents as polyneuropathy in 6-21% of patients. Connective tissue diseases most often associated with vasculitis include the following:

Nonsystemic vasculitic neuropathy

Localized vasculitis affects either the central nervous system (primary central nervous system angiitis) or the peripheral nervous system. Nonsystemic vasculitic neuropathy involves small and medium-sized arteries.

Clinical and histologic presentation is similar to that of neuropathy observed in systemic vasculitis but without any other organ involvement.

Nonsystemic vasculitic neuropathy represents one third of all vasculitic neuropathies. Prognosis is better than that of systemic vasculitic neuropathy.

Paraneoplastic vasculitic neuropathy

Paraneoplastic vasculitic neuropathy is a rare paraneoplastic syndrome characterized by nonsystemic subacute vasculitic neuropathy. The cancers most commonly associated with paraneoplastic vasculitic neuropathy are small cell lung cancer and lymphomas.

Previous
 
 
Contributor Information and Disclosures
Author

Abbas Mehdi, MD Director, MDA Center of Central California; Consulting Staff, Department of Neurology, California Neurological Center, Inc

Abbas Mehdi, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, American Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Said R Beydoun, MD Chief, Professor, Department of Neurology, University Hospital, University of Southern California

Said R Beydoun, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Additional Contributors

Norman C Reynolds, Jr, MD Neurologist, Veterans Affairs Medical Center of Milwaukee; Clinical Professor, Medical College of Wisconsin

Norman C Reynolds, Jr, MD is a member of the following medical societies: American Academy of Neurology, Association of Military Surgeons of the US, International Parkinson and Movement Disorder Society, Sigma Xi, Society for Neuroscience

Disclosure: Nothing to disclose.

References
  1. Kernohan JW, Woltman HW. Periarteritis nodosa: a clinicopathologic study with special reference to the nervous system. Arch Neurol Psychiatry. 1938. 39:655-86.

  2. Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain. 1987 Aug. 110 ( Pt 4):843-53. [Medline].

  3. Davies L, Spies JM, Pollard JD, McLeod JG. Vasculitis confined to peripheral nerves. Brain. 1996 Oct. 119 ( Pt 5):1441-8. [Medline].

  4. Kissel JT, Riethman JL, Omerza J, Rammohan KW, Mendell JR. Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann Neurol. 1989 Mar. 25(3):291-7. [Medline].

  5. Murthy JM, Sundaram C, Meena AK. Nonsystemic vasculitic neuropathy. J Assoc Physicians India. 1998 Feb. 46(2):204-6. [Medline].

  6. Larrode P, Ramon y Cajal S, Iníguez C, Dominguez M, Sanz JM, Morales F. [Isolated vasculitis of the peripheral nervous system]. Neurologia. 1997 May. 12(5):197-9. [Medline].

  7. Collins MP, Mendell JR, Periquet MI, Sahenk Z, Amato AA, Gronseth GS. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology. 2000 Sep 12. 55(5):636-43. [Medline].

  8. Sanchez GM, Villanueva-Haba VE, Sevilla Mantecon T, Mayordomo Fenandez F, Vilchez Padilla JJ. Nonsystemic vasculitic neuropathy. Neurologia. 2002. 17:613-5.

  9. Vrancken AF, Said G. Vasculitic neuropathy. Handb Clin Neurol. 2013. 115:463-83. [Medline].

  10. Gwathmey KG, Burns TM, Collins MP, Dyck PJ. Vasculitic neuropathies. Lancet Neurol. 2014 Jan. 13(1):67-82. [Medline].

  11. Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology. 2003 Sep 9. 61(5):623-30. [Medline].

  12. Mathew L, Talbot K, Love S, Puvanarajah S, Donaghy M. Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome. QJM. 2007 Jan. 100(1):41-51. [Medline].

  13. Kissel JT, Slivka AP, Warmolts JR, Mendell JR. The clinical spectrum of necrotizing angiopathy of the peripheral nervous system. Ann Neurol. 1985 Aug. 18(2):251-7. [Medline].

  14. Kararizou E, Davaki P, Karandreas N, Davou R, Vassilopoulos D. Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases. J Rheumatol. 2005 May. 32(5):853-8. [Medline].

  15. Jayne D. Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford). 2000 Jun. 39(6):585-95. [Medline].

  16. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb. 37(2):187-92. [Medline].

  17. Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. 1967 Jul. 43(1):8-14. [Medline].

  18. Moore PM, Cupps TR. Neurological complications of vasculitis. Ann Neurol. 1983 Aug. 14(2):155-67. [Medline].

  19. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999 Jan. 78(1):26-37. [Medline].

  20. Sehgal M, Swanson JW, DeRemee RA, Colby TV. Neurologic manifestations of Churg-Strauss syndrome. Mayo Clin Proc. 1995 Apr. 70(4):337-41. [Medline].

  21. Hirahara T, Yamashita S, Misumi Y, Kawakami K, Hori H, Honda S, et al. Gait disturbance due to foot drop is refractory to treatment in nonsystemic vasculitic neuropathy. Eur Neurol. 2014. 71(3-4):180-6. [Medline].

  22. Abgrall S, Mouthon L, Cohen P, et al. Localized neurological necrotizing vasculitides. Three cases with isolated mononeuritis multiplex. J Rheumatol. 2001 Mar. 28(3):631-3. [Medline].

  23. Hawke SH, Davies L, Pamphlett R, et al. Vasculitic neuropathy. A clinical and pathological study. Brain. 1991 Oct. 114 ( Pt 5):2175-90. [Medline].

  24. Johnson R, Griffin J. Current Therapy in Neurologic Disease. 5th ed. Philadelphia: BC Decker;. 1997.

  25. Kissel JT, Mendell JR. Vasculitic neuropathy. Neurol Clin. 1992 Aug. 10(3):761-81. [Medline].

  26. Olney RK. Neuropathies associated with connective tissue disease. Semin Neurol. 1998. 18(1):63-72. [Medline].

  27. Said G. Vasculitic neuropathy. Curr Opin Neurol. 1999 Oct. 12(5):627-9. [Medline].

  28. Satoi H, Oka N, Kawasaki T, et al. Mechanisms of tissue injury in vasculitic neuropathies. Neurology. 1998 Feb. 50(2):492-6. [Medline].

  29. Vedeler CA. Inflammatory neuropathies: update. Curr Opin Neurol. 2000 Jun. 13(3):305-9. [Medline].

 
Previous
Next
 
Diagnostic classification of peripheral vasculitic neuropathy (PVN).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.